Phuturdex › Diseases › Heart disease
Drugs in development · updated 30 October 2026
Heart disease: drugs in development
As of 30 October 2026 there are 20 active clinical trials (recruiting or ongoing, phases I–III) on 17 drugs for heart disease. 7 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Retatrutide | III | 1 | NCT06383390 |
| Ziresovir | II–III | 1 | NCT07658534 |
| AC01 | II | 1 | NCT07584967 |
| KPL-387 | II | 1 | NCT07288216 |
| LX2006 | II | 1 | NCT07721025 |
| Orticumab | II | 1 | NCT06927739 |
| ResveratrolTrans-Resveratrol | Early I | 1 | NCT04449198 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| ColchicineColchicin, Lodoco® | III | 5 | NCT05633810 |
| AcoramidisAttruby®, Beyonttra® | III | 2 | NCT07116473 |
| AspirinVazalore®, Durlaza® | III | 2 | NCT05633810 |
| BupivacaineExparel, Bupivacain | II–III | 1 | NCT06077422 |
| EplerenoneEpleronone, Inspra® | II–III | 1 | NCT07892664 |
| HeparinUnfractionated heparin, Heparin Sodium Preservative Free® | III | 1 | NCT04374799 |
| Lumason | III | 1 | NCT06400004 |
| OrforglipronFoundayo® | III | 1 | NCT07241390 |
| TicagrelorBrilinta®, Brilique® | III | 1 | NCT05476991 |
| FEIBA | II | 1 | NCT07032792 |
Sorted by most advanced phase and number of active trials.
All 17 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Heart failure 104 drugs
- Atrial fibrillation 32 drugs
- Coronary artery disease 34 drugs
- Myocardial infarction 26 drugs
- Myocardial infarction with ST segment elevation 22 drugs
- Cardiomyopathies 23 drugs
- Cardiovascular disease 71 drugs
- Hypertrophic cardiomyopathy 16 drugs
- Inflammation 85 drugs
- Acute coronary syndrome 17 drugs
- Heart Arrest 13 drugs
- Aortic valve stenosis 13 drugs
Broader categories
- Cardiovascular disease 71 drugs
- Vascular disease 16 drugs
- Nervous System Diseases 39 drugs
- Metabolic disease 30 drugs
- Nutritional and metabolic diseases 5 drugs
- Brain Diseases 23 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D006331 “Heart Diseases”.